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The associations between depressive symptoms and hypersomnia are complex and often bidirectional. Of the
many disorders associated with excessive sleepiness in the general population, the most frequent are mental health
disorders, particularly depression. However, most mood disorder studies addressing hypersomnia have assessed
daytime sleepiness using a single response, neglecting critical and clinically relevant information about symptom
severity, duration and nighttime sleep quality. Only a few studies have used objective tools such as
polysomnography to directly measure both daytime and nighttime sleep propensity in depression with normal
mean sleep latency and sleep duration. Hypersomnia in mood disorders, rather than a medical condition per se, is
more a subjective sleep complaint than an objective finding. Mood symptoms have also been frequently reported
in hypersomnia disorders of central origin, especially in narcolepsy. Hypocretin deficiency could be a contributing
factor in this condition. Further interventional studies are needed to explore whether management of sleep
complaints improves mood symptoms in hypersomnia disorders and, conversely, whether management of mood
complaints improves sleep symptoms in mood disorders.
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Excessive daytime sleepiness (EDS) is commonly assumed
to result from disturbed or insufficient sleep. Various
symptoms associated with EDS have been reported in the
literature, indicating a multifactorial mechanism [1]. EDS
is associated with many sleep disorders, such as insomnia,
obstructive sleep apnea syndrome, circadian rhythm sleep
disorders, and restless legs syndrome. In addition, it is a
marker symptom in rare hypersomnias of central origin.
However, the most frequent associations are mental health
disorders and, particularly, depression [2].
A large cross-sectional study of independent risk fac-
tors associated with EDS in the general population found
that current depression is a major factor, the result being
unchanged after controlling for antidepressant use [3].
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reproduction in any medium, provided the oradults in the US [1]. However, using an EDS frequency
of at least three times per week for at least three months
with normal nighttime sleep duration, the prevalence
was 4.7% and 1.5% in the presence of associated daytime
impairment. In that study, EDS was associated with
insufficient sleep, several sleep disorders, and general
organic diseases in addition to psychiatric conditions
(including anxiety and depressive disorders) and hyp-
notic and antidepressant use [1]. We previously reported
strong associations between EDS and bipolar-II disorder
as well as major depressive disorder (MDD) with atypical
symptom features in a general elderly population [4].
Moreover, severity of EDS occurrence increased the risk
of subsequent depression in elderly patients at four-year
follow-up [5].
Cross-sectional studies have also repeatedly noted fre-
quent sleep disturbances in depression [6]. Both EDS
and insomnia form part of the clinical algorithm used to
diagnose depression [7] and were initially considered to
be a consequence of the disorder due to disturbances in
monoamine activity [8]. Recent studies have suggested
that sleep disorders may precede depression [5] and that
non-depressed subjects with a family history of depressiontral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malities [9]. The mechanisms by which EDS contributes
to the development of depressive symptoms remain un-
clear. Physiological hypotheses have implicated genes as-
sociated with both the monoamine and circadian systems,
related to stress-induced arousal responses and subse-
quent overactivity of the hypothalamic-pituitary-adrenal
axis or, alternatively, mediated by increased activation of
REM sleep mechanisms [10].
In this article, we describe hypersomnia assessment
methods, define hypersomnia in mood disorders, and re-
view studies that have examined mood disorder symp-
toms in hypersomnias of central origin.
Definition and assessment of hypersomnias
In the literature, hypersomnia refers to a specific sleep-
disorder-related diagnosis, such as narcolepsy in the
International Classification of Sleep Disorders (ICSD-2)
[11], or an associated symptom in various diagnostic en-
tities, such as MDD in the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) [7]. In the latter condition, the predomin-
ant complaint is excessive sleepiness for at least one
month (or less if recurrent), evidenced by either prolonged
sleep episodes or daytime sleep episodes occurring almost
daily.
Excessive daytime sleepiness
The terms ‘hypersomnia,’ ‘excessive somnolence,’ ‘exces-
sive sleepiness’ and ‘EDS’ are often used interchangeably,
and EDS tends to be considered a disease or disorder.
However, EDS is a symptom of a sleep disorder or other
disease but not a disease per se [12]. Another problem
with EDS is its definition, which is based mainly on one
or two questions in epidemiological investigations, mak-
ing for large differences across studies. The frequency,
severity and duration of EDS greatly affect its preva-
lence, which ranges from 4% to 30% [1,12]. For example,
ICSD-2 defines EDS as ‘an inability to remain fully alert
or awake, or a propensity to nod or doze when seden-
tary, during the wakefulness portion of the sleep/wake
cycle. This occurs daily or almost daily for at least three
months [11].’ In clinical practice, EDS assessment usu-
ally involves self-report questionnaires. The most widely
used is the Epworth Sleepiness Scale: the patient is
instructed to make a probability judgment about the ex-
pectation of ‘dozing’ in eight different circumstances (for
example, sitting and reading), a score above 10 being
pathological [13]. Other questionnaires involve a moment-
ary assessment of sleepiness, such as the Stanford Sleepi-
ness Scale [14] and the Karolinska Sleepiness Scale [15].
Objective measures of EDS also exist. The Multiple
Sleep Latency Test (MSLT) is the most commonly used
[16]. The patient lies in bed in a darkened room in thedaytime and tries to fall asleep. The patient takes five
20-minute naps, each two hours apart. Mean sleep la-
tency <8 minutes is pathological and <5 minutes is se-
vere. However the EDS complaint rarely correlates with
objective findings on the MSLT. An alternative to the
MSLT is the Maintenance Wakefulness Test (MWT),
which assesses the capacity to maintain wakefulness
[17]. During two or four 20- or 40-minute sessions, the
patient sits in bed and attempts to remain awake. The
most sensitive four-trial 40-minute MWT protocol con-
siders latency <19 minutes as abnormal [17,18]. In rare
circumstances, prolonged 24-hour continuous sleep re-
cording is required to assess the degree of sleepiness.
Excessive quantity of nocturnal sleep
Abnormally long nighttime sleep may be a major com-
plaint in central hypersomnias (that is, idiopathic hyper-
somnia) and in the presence of associated conditions.
Excessive sleep quantity varies across subjects and with
age, younger individuals having longer nighttime sleep.
The pathological cut-off of 9, 10, or 11 hours across the
night and the 24-hour period remains controversial [19].
Based on a recent large cross-sectional telephone survey
of adults in the US, we found that 6.3% of the sample
reported a sleep duration of 9 hours or greater during
the main sleep episode, and 8.4% reported sleeping at
least 9 hours per 24-hour period [20]. In addition, 25.1%
of subjects sleeping ≥9 hours per night and 40.1% of
subjects sleeping ≥9 hours per 24-hour period also expe-
rienced excessive sleepiness. Moreover, excessive night-
time sleep is rarely an isolated symptom, as it frequently
coexists with other organic, mental, and sleep disorders.
Because most studies report the total amount of night-
time sleep or sleep across a 24-hour period using only
one or two questions, a sleep diary or actigraphy would
be useful to validate the data. A sleep diary is a daily log
used to record sleep-wake patterns over a period of weeks
[21]. Extensively used in insomnia and circadian rhythm
sleep disorders, the sleep diary allows quantifying ex-
tended nocturnal sleep and daytime naps along with
available day-to-day and weekday-to-weekend variability
symptoms. However, all these data are subjective, with fre-
quent differences between the patient’s perceived night-
time and daytime sleep and objective sleep recording, and
a tendency to overestimate sleep over 24 hours. Much less
expensive than polysomnography (PSG), wrist actigraphy
is a promising clinical tool for measuring rest–activity pat-
terns and estimates of sleep–wake patterns over multiple
days and nights [22,23]. Actigraphy permits the documen-
tation of extended nocturnal sleep and daytime naps in
clinical hypersomnia populations, but again with a ten-
dency to overestimate sleep instead of rest, and to under-
estimate wake during the day [24]. The standard objective
measure of nocturnal sleep is expensive in-lab PSG. PSG
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involving six to ten hours of recording, which prevents
gathering information about extended nocturnal sleep or
napping behavior. Prolonged and continuous 24-hour
PSG under an ad-libitum protocol can objectively meas-
ure extended nocturnal sleep [25,26]. This procedure is
rarely performed however, and only in a few sleep labora-
tories at high cost, in the absence of standardization or
age- and gender-normative data. Nevertheless, without this
procedure, it is difficult to distinguish whether hypersomnia
consists of actual extended sleep or whether it simply rep-
resents an extra time spent in bed without necessarily
sleeping, known as clinophilia.
Hypersomnia associated with mood disorders
Diagnostic criteria for hypersomnia associated with mood
disorders are described in three classification systems: the
DSM-IV-TR [7], the ICSD2 [11], and the International
Classification of Diseases (ICD-10) [27]. A complaint of
excessive sleep quantity or EDS is always required. The
predominant complaint of excessive sleepiness, evidenced
by either prolonged or daytime sleep episodes occurring
almost daily, is mandatory for a hypersomnia diagnosis
related to other mental disorders under the DSM-IV. A
complaint of EDS or excessive sleep is required for the
diagnosis of hypersomnia not due to substance abuse or
known physiological condition (nonorganic hypersomnia)
under the ICSD-2. Excessive daytime sleep or sleep attacks
not accounted for by inadequate sleep and/or prolonged
transition to the fully aroused state upon awakening (sleep
drunkenness) are criteria for non-organic hypersomnia
under the ICD-10.
The ICD-10 and DSM-IV-TR include a symptom
duration criterion of at least one month, and both imply
either distress or impairment in social and/or occupa-
tional areas. The ICSD-2 is the only system that recom-
mends objective measurement with PSG. However, it
does not stipulate the daytime or nocturnal sleep dur-
ation, assessment procedures, or pathological cut-offs.
Reduced sleep efficiency, increased sleep frequency, and
increased number of awakenings together with ‘variable
but often normal’ mean sleep latency on the MSLT were
only proposed.
The proposed DSM-5 criteria for sleep-wake disorders
nosology planned for publication this year included
major changes regarding hypersomnia with elimination
of the diagnosis of ‘primary hypersomnia’ in favor of
‘hypersomnia disorder,’ with concurrent specification of
clinically comorbid conditions [28]. These modifications
will also lead to elimination of ‘sleep disorder related to
another mental disorder’ and ‘sleep disorder due to a
general medical condition,’ in favor of ‘hypersomnia dis-
order’ with concurrent specification of clinically comor-
bid medical and psychiatric conditions. Sleep disordersper se are frequently accompanied by depression, anxiety
and other cognitive mental status changes that warrant
independent clinical attention and must be addressed in
treatment management. As the primary users of DSM
are mental health and general medical clinicians, not
sleep disorder specialists, new DSM5 sleep-wake disor-
ders criteria also included aggregation of hypersomnia
disorder and narcolepsy without cataplexy, which will be
distinguished from narcolepsy-cataplexy/hypocretin-1
deficiency disorder. Based on a recent cross-sectional
telephone survey, a new definition of hypersomnia has
been proposed in the upcoming DSM-5 revision includ-
ing a frequency of ‘excessive sleepiness’ (defined by ei-
ther recurrent periods of irrepressible need to sleep or
to nap within the same day; recurrent naps within the
same day; a nonrestorative/unrefreshing prolonged main
sleep episode of nine hours or more; and/or confusional
arousals-sleep drunkenness) at least three times per week
for at least three months, despite normal main sleep dur-
ation lasting seven hours or longer, with significant day-
time distress/impairment leading to a final prevalence of
1.5% [1].
Definition and assessment of mood disorders
Diagnostic criteria for MDD are based on the presence of
either sad mood and/or anhedonia plus four out of nine
additional symptoms, including insomnia or hypersomnia
[7]. Atypical depression may be considered a distinct en-
tity or else a phase of MDD that evolves over time when
the disorder becomes more chronic. To be qualified as
having atypical features, a depressed patient must experi-
ence significant mood reactivity plus at least two other
features, also including hypersomnia [7]. Dysthymic dis-
order (DD) diagnosis requires low mood present almost
daily for two years plus at least two other MDD symp-
toms, including hypersomnia [7]. Three bipolar-related
diagnoses (BD) have been individualized: BD-I, BD-II, and
cyclothymia. Sleep disturbances are listed as symptoms of
each BD subtype, with reduced need for sleep for manic
and hypomanic episode and insomnia or hypersomnia for
depressive episode. The initial description of seasonal
affective disorder (SAD) stipulated frequent occurrence
of hypersomnia, dysphoria, hyperphagia, and weight
gain [29]. Currently, SAD is not considered a separate
disorder, but instead a ‘course specifier’ that may exist
in MDD or BD [7]. Mood disorders are generally diag-
nostically assessed with the Structured Clinical Inter-
view for DSM-IV Axis 1 Disorder [30]. This instrument
is a semi-structured interview for making standardized,
reliable, and accurate diagnoses of the DSM-IV Axis 1
disorders. Self- or hetero-report questionnaires are also
commonly used to quantify mood symptom severity.
Self-report questionnaires include the Beck Depression
Inventory (BDI-II) [31], the Hamilton Depression Rating
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the Zung Rating Scale for Depression [34], the Hospital
Anxiety and Depression Scale [35], and the Inventory of
Depressive Symptomatology (self-rating, IDS-SR30) [36].
These instruments are completed by the patients them-
selves. Note that the IDS also has a clinician-rated ver-
sion (IDS-C30) [36].
However, these questionnaires should be interpreted
with caution when assessing the presence and severity of
depressive symptoms, higher scores being potentially
without a diagnosis of mood disorder and vice versa. Simi-
lar scores using these questionnaires may also obscure im-
portant individual differences in the relative severity and
frequency of somatic/affective versus cognitive symptom-
atology. Accordingly, we must emphasize that somatic
and cognitive symptoms can be signs of physical illness
and that self-report questionnaires often over-identify de-
pression in clinical populations [37], such as patients with
central hypersomnias.
Hypersomnia associated with mood disorders
Subjective assessment of hypersomnia
The hypersomnia symptoms associated with mood dis-
orders are not specific and may include non-imperative
EDS, long non-refreshing naps, long sleep time, and
sleep inertia. EDS should be distinguished from insuffi-
cient sleep and fatigue. Fatigue is not necessarily relieved
by increased sleep and may be unrelated to sleep quan-
tity or quality. However, it is difficult to differentiate be-
tween EDS and fatigue, which may overlap considerably
in mood disorders. It is also particularly difficult to dif-
ferentially diagnose between idiopathic hypersomnia and
less severe forms of depression (for example, dysthymia).
Albeit a diagnostic symptom for mood disorders,
hypersomnia is largely understudied in this area. A recent
review reported widely varying estimates of hypersomnia
in MDD across age, gender and studies, ranging from 8.9%
in childhood (<13 years) to 75.8% in young adulthood [2],
with a higher prevalence in females. Few studies have ex-
plored the presence of hypersomnia symptoms in MDD
with atypical features, with frequency varying from 24% to
56% [38,39]. The large frequency range likely reflects am-
biguous definitions of hypersomnia, which vary between
studies and are mostly based on a response to a single
question [40-42]. The basis of hypersomnia in MDD is
poorly understood; one may hypothesize that hypersomnia
is related to abnormal sleep homeostasis in MDD. Interest-
ingly, a recent high density electroencephalography study
suggested that the presence of hypersomnia in MDD is as-
sociated with reduced parieto-occipital slow wave activity
compared to those without hypersomnia [43].
Hypersomnia assessed with a single yes/no response
(for example, ‘sleeping too much’) was found to be re-
fractory after antidepressant intake, persisting even whenother symptoms had remitted [44,45]. Hypersomnia may
also predict the onset of a major depressive episode
[5,42], and hypersomnia persistence after depressive
symptoms have been managed may be a condition in
those at risk for developing recurrent depressive epi-
sodes [41,46].
In a cohort of consecutive BD-II and MDD outpa-
tients, ‘increased sleep’ was reported by 37.6% and 24%,
respectively [38]. Another study in BD exploring hyper-
somnia complaints that used several questionnaires and
a sleep diary for seven days between episodes showed
that hypersomnia may predict the risk of future depressive
symptoms, with no interaction with baseline depressive
symptoms or medication use [47]. Lifetime hypomanic
episodes were also associated with persistent EDS in an
elderly population [4]. The frequency of hypersomnia
symptoms in SAD ranged from 67% to 76% across studies
[2,48-52]. However, these studies used different diagnostic
tools to assess sleep complaints. One study used an ori-
ginal methodological approach to explore hypersomnia
complaints in patients with SAD: a standard interview
guide, questionnaires, and sleep diaries [53]. Results indi-
cated longer self-reported total hours of sleep in winter
than in summer but with large differences between assess-
ment methods, and again with a tendency to overestimate
total sleep time using self-reports.
Objective assessment of hypersomnia
A few studies have used objective methods to investigate
extended nocturnal sleep and EDS in mood disorders,
but all reported no difference in mean sleep latency or
sleep duration between patients with mood disorders
and healthy controls. REM sleep was almost absent dur-
ing daytime naps in the depressed phase of patients with
BD [54]. Hypersomnia complaints were independent of
the mean sleep latency and were related more to lack of
interest and decreased energy due to depression in BD
[54]. Another study revealed neither pathological sleep
latencies on the MSLT nor abnormal total sleep time on
prolonged PSG in patients with hypersomnia associated
with mood disorders, that is, dysthymia, BD, and recur-
rent MDD [55]. Normal MSLT latency was also reported
in dysthymic patients compared to patients with idio-
pathic hypersomnia and healthy controls [56]. Using the
PSG and a non-conventional objective measure of EDS
(that is, two 60-minute naps at 9:00 and 12:30), Vgontzas
and co-workers have compared the nighttime and the
objective sleepiness of drug-free patients with diagnosis
of primary (idiopathic) versus psychiatric hypersomnia
(that is, mood, somatoform, anxiety, and personality dis-
orders) [57]. This group found that patients with psychi-
atric hypersomnia, although having complaints of EDS,
showed both during the day and during the night lower
sleep propensity (that is, higher sleep latency and total
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and controls [57].
Taken together, there is no objective evidence
supporting the view that patients with mood disorder
have either abnormal mean sleep latency on the MSLT
or objective extended nocturnal sleep. However, these
patients spent a substantial amount of time in bed, ac-
knowledged as ‘resting’ more than ‘sleeping’ (called
clinophilia), with major distress and impacts on the nat-
ural course of mood disorders.
One may question whether the diagnosis of hyper-
somnia requires objective evidence of daytime/nighttime
sleepiness or hypersomnia may be resumed as a ‘subject-
ive sleep complaint.’ The complaint of EDS is rarely
corroborated by the MSLT results, particularly in the
context of associated mood disorders. Paralleling PSG-
MSLT studies of hypersomnia in mood disorders, PSG
evidence for insomnia often does not match self-report,
and yet insomnia is currently considered an independent
disorder. We do believe that hypersomnia diagnosed by
a structured clinical interview as in proposed DSM-5
criteria merits clinical attention [28]. Thus, hypersomnia
associated with mood disturbances may be a clinically-
defined condition with significant socio-economic burden
[58] that may justify a treatment. To date, no pharmaco-
logical drugs have been approved to manage hypersomnia
in depressive disorders. The management bias is a con-
cern, with potential interactions between EDS, extended
nocturnal sleep complaints and drug intake. Some basic
recommendations can be proposed, such as avoiding psy-
chotropic sedative drugs (that is, benzodiazepine) and giv-
ing priority to noradrenergic antidepressant treatments
for their action on the wake drive. Treatment with antide-
pressants, such as selective serotonin reuptake inhibitors
and reuptake inhibitors of serotonin and noradrenalin,
rather than psychostimulants, may be considered for pa-
tients when a mood disorder cannot be definitely ruled
out as the cause of hypersomnia. However, complaints of
EDS and extended nocturnal sleep may persist as refrac-
tory symptoms, despite adequate medication or behavioral
and cognitive therapy that improve other symptoms. Fur-
ther assessments, including objective measures of EDS,
may then be useful to formally exclude an underlying cen-
tral hypersomnia disorder.
Mood symptoms associated with hypersomnia
disorders
Comorbidity between hypersomnia disorders and mood
symptoms, particularly depression, is frequently reported
in both clinical and research settings. However, the causal
relationship between the two conditions remains unclear.
Hypersomnia symptoms may also be misdiagnosed as de-
pression, because MDD symptoms according to the DSM-
IV-TR are common features of hypersomnia disorders.Narcolepsy with cataplexy
Narcolepsy is an orphan sleep disorder (0.026% of the
general population) characterized by a clinical history of
EDS and abnormal manifestations of dissociated REM
sleep, such as cataplexy (that is, sudden loss of muscle
tone triggered by strong emotions), hypnagogic halluci-
nations, and sleep paralysis [59]. Narcolepsy typically
starts during adolescence, a critical period of normal de-
velopment and interpersonal relationship building [60].
Cataplexy is the best clinical diagnostic marker for the
disease, occurring in 70% to 80% of patients. Two separate
entities are individualized: narcolepsy with and without
cataplexy [11]. Narcolepsy diagnosis requires nocturnal
PSG recording followed by the MSLT, the latter showing a
mean sleep latency <8 minutes and two or more sleep on-
set REM periods (SOREMPs).
For 120 years after it was identified, narcolepsy was at-
tributed to psychiatric etiologies [61]. In the 2000s, how-
ever, it was determined that when cataplexy is present,
narcolepsy is almost always caused by an immune-
mediated destruction of orexin/hypocretin neurons lo-
cated in the lateral hypothalamus [62,63]. Accordingly,
low-undetectable cerebrospinal hypocretin-1 is observed
in almost all cases of narcolepsy with cataplexy, but in
only 10% to 20% in narcolepsy without cataplexy [64-67].
Studies linking loss of hypocretin neurons to human
narcolepsy have spurred interest in improving the disease
phenotype. Neuroanatomical studies indicate that hypo-
cretin projections are widespread, including the cortex,
the basal forebrain, limbic structures (for example, amyg-
dala, ventral tegmental area), the thalamus, most of the
brainstem (that is, locus coeruleus, raphe nucleus, and cho-
linergic tegmental nuclei) and the spinal cord [68]. The
hypocretins act primarily as excitatory neurotransmitters
to control monoaminergic and cholinergic neuron activity.
Hypocretin deficiency induces a cholinergic–monoaminer-
gic imbalance, with primary effects on vigilance as well as
other functions, including mood regulation. Because
hypocretins are also involved in neuroendocrine functions
and stress reactions through stimulation of the hypothal-
amus–pituitary–adrenal axis, hypocretin deficiency per se
may trigger mood disturbances and psychological alter-
ations through diverse pathways.
High levels of psychopathology were frequently reported
in cross-sectional studies in narcolepsy, with a high preva-
lence of self-reported depressive symptoms [69-72]. In a
lifetime approach case–control study using DSM-IV-TR
criteria, increased psychotic symptoms were found in nar-
colepsy with cataplexy, with no increase in depression
frequency [73]. However, psychotic-like symptoms were
induced by amphetamine intake and not by the disease
per se, and symptoms were resolved when the dose was
lowered or treatment changed to modafinil [73]. Another
case–control study found mood disorder symptoms in
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cant difference was found between patients and controls
regarding the formal mood disorder diagnosis [74]. In
contrast, more than half the patients had anxiety or panic
attacks and 35% had an anxiety disorder [74]. Regarding
depressive symptomatology, the frequency of moderate to
severe symptoms ranged from 15% to 37% in narcolepsy
[75-78]. Our large cross-sectional narcolepsy study found
that depressive symptoms (using the BDI-II) were associ-
ated with greater EDS severity, greater alterations in
physical and mental health quality of life, as well as the
presence of REM sleep manifestations, such as cataplexy,
hypnagogic hallucinations and sleep paralysis [76]. Al-
though depressed patients generally tend to overscore on
any scale, these data reinforced reported associations be-
tween depressive symptoms, hypnagogic hallucinations,
and sleep paralysis in a population-based study [79]. A
similar frequency of depressive symptoms was found in
other narcoleptic populations and using other question-
naires [80-82]. Interestingly, in a five-year cohort study of
patients with narcolepsy-cataplexy, mood symptoms
remained relatively stable, with 25% of patients showing
constant moderate to severe mood symptoms across as-
sessments [81]. Globally, a high frequency of depressive
symptoms has been systematically reported in narcolepsy
with cataplexy, supporting the hypothesis of an endogen-
ous depression [61,76,81]. This condition was previously
suggested based on reduced nighttime REM sleep latency,
increased REM sleep pressure and sleep fragmentation in
both narcolepsy and major depression.
Although there is no cure for narcolepsy, psycho-
stimulants such as modafinil, methylphenidate, amphet-
amine, and sodium oxybate are used to treat EDS and
sleep attacks. Cataplexy is managed with sodium oxybate
and antidepressant drugs [59]. Hence, most drugs used
to manage cataplexy have mood-modifying properties.
When assessing treatment effects on disease severity and
psychological consequences, we observed that patients
with narcolepsy with cataplexy treated with anticataplectics
(mainly tricyclic agents and selective serotonin reuptake in-
hibitors) had more depressive symptoms and greater qual-
ity of life alterations compared to patients treated with
stimulants alone [76]. Higher baseline severity of REM
sleep manifestations would normally lead to higher pre-
scriptions of anticataplectics. However, our study revealed
that anticataplectics at doses prescribed for cataplexy
management were ineffective in treating depressive symp-
toms [76].
Recent studies also support the role of specific
hypocretin receptors in the modulation of depression-
like behavior. A behavioral mice study after genetic or
pharmacologic inhibition of hypocretin receptor signaling
suggested that the hypocretin activity balance at either re-
ceptor 1 or receptor 2 produced an anti-depressant- orpro-depressant-like effect depending on the subtype
activated [83].
Outside of the narcolepsy scope, some human studies
have compared the levels of hypocretin-1 in the cerebro-
spinal fluid (CSF) in patients with mood disorders with
the levels in healthy controls leading to controversial
results. A reduced amplitude in diurnal variations of
hypocretin-1 has been found in patients with bipolar or
unipolar depression [84]. Brundin and co-workers found
that suicidal patients with major depressive disorder had
significantly lower CSF hypocretin levels than other sui-
cidal patients [85]. In contrast other studies found simi-
lar CSF hypocretin-1 levels in patients with MDD and
controls [86,87]. In addition, CSF hypocretin-1 levels did
not correlate with the severity of depressive episode, the
symptoms of depression or the number of episodes
[86,87]. To our best knowledge, no studies have reported
whether CSF hypocretin-1 levels are altered in depres-
sive patients with hypersomnia or not. However, some
recent results hold promise for the use of non-selective
hypocretin-1 and −2 agonists and antagonists to treat
several neuropsychiatric disorders, including narcolepsy,
insomnia, and drug addiction. Nevertheless, potential
unwanted side effects must be carefully monitored.
Idiopathic hypersomnia
The prevalence of idiopathic hypersomnia (IH) in the
general population is unknown. The age of symptom on-
set varies, but is frequently between 10 and 30 years
[88,89]. Its pathophysiology is almost totally unknown,
with no clear biological or genetic markers. Two forms
of IH have been individualized: IH with and without
long sleep time (LST) [11]. IH with LST is characterized
by three major symptoms: (1) constant daily excessive
sleepiness with unwanted and prolonged (≥1 hour) naps,
less irresistible than in narcolepsy, and unrefreshing irre-
spective of duration; (2) long nocturnal sleep, uninter-
rupted and prolonged, with ≥10 hours of sleep; and (3)
difficulty awakening after nighttime or daytime sleep,
with frequent problems reacting adequately to external
stimuli upon awakening, called ‘sleep drunkenness’ or
‘sleep inertia.’ IH without LST is characterized by iso-
lated EDS. Daytime sleep episodes may be more irresist-
ible, shorter, and more refreshing than in IH with LST.
Nocturnal sleep in IH without LST is normal, with rare
sleep inertia. However, some patients share clinical symp-
toms of both forms of IH, with prolonged nocturnal sleep
time without sleep inertia, and others with nocturnal sleep
of normal duration but with major sleep drunkenness
[25,88,89]. Other symptoms such as mood changes (but
not major depression), headache, and manifestations of
neurovegetative impairment may be reported. IH diagnosis
is based on clinical features and PSG followed by the MSLT
(for IH without LST) or 24-hour continuous PSG under an
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ively confirm hypersomnia, ascertain the diagnosis and rule
out other causes of hypersomnia (for example, insufficient
sleep, sleep apnea syndrome, narcolepsy).
Depressive symptoms were noted in 15% to 25% using
clinic-based samples of patients affected with IH, values
being always higher than in the general population
[55,56,76,90]. Mood changes not qualifying for a mood
disorder diagnosis may precede or follow EDS onset and
evolve independently. However, MDD (being an exclu-
sion criterion) is incompatible with an IH diagnosis, un-
like narcolepsy-cataplexy, which is potentially associated
with mood disorders. Hence, it is unrealistic to estimate
the frequency of mood disorders and depressive symp-
tom severity in both forms of IH. However, we may
suggest a bridge between hypersomnia associated with
mood disorders or with depressive symptoms only and
IH, with difficulty distinguishing the two conditions in
some cases. Prospective studies are needed to unravel
this issue, more specifically, to clarify whether mood
changes in IH are consequent to difficulty adapting to
the disease or whether they indicate a primary brain
dysfunction.
Behaviorally induced insufficient sleep syndrome
Behaviorally induced insufficient sleep syndrome (BIISS),
or self-induced sleep restriction, is an individualized
clinical entity in the ICSD-2 [11]. BIISS requires three
criteria: (1) EDS complaint lasting at least three months,
(2) shorter than expected habitual main sleep episode
and (3) extended sleep when the habitual sleep schedule
is not maintained (weekends and holidays). No epidemio-
logical study has investigated BIISS prevalence in the
general adult population. However, one study reported a
7.1% prevalence in outpatient clinic patients with a com-
plaint of EDS [91]. From computerized self-report ques-
tionnaires, estimated BIISS prevalence was 10.4% in a
large Norwegian cohort of students and associated with
severe self-reported depressed mood [92]. Interestingly,
the presence of BIISS was recently found to increase sui-
cidal tendencies in Korean adolescents, even after control-
ling for BDI scores [93]. The limitations of these studies
are the use of self-report measures and cross-sectional
designs. Longitudinal approaches are needed to confirm
the causal relationship between BIISS and mood disorder
development.
Conclusions
The associations between depression and daytime and
nighttime sleepiness are complex and potentially bidirec-
tional. The greatest challenges in the literature are the
varying definitions of hypersomnia and the wide clinical
heterogeneity of depression. Although objective tools
such as PSG enable direct sleep measurement, they areunrealistic for use in large-scale population-based stud-
ies. Given the different methods used, the conflicting
results are unsurprising. Nevertheless, no objective
hypersomnia has been recorded consequent to mood
disorders. Conversely, mood symptoms are frequently
reported in hypersomnia disorders of central origin.
Further interventional studies are needed to explore
whether the management of sleep complaints improves
mood symptoms in hypersomnia disorders and whether
the management of mood complaints improves sleep
symptoms in mood disorders.
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